83 related articles for article (PubMed ID: 29300135)
1. Non-clinical pharmacokinetic profiles of rovatirelin, an orally available thyrotropin-releasing hormone analogue.
Kobayashi K; Abe Y; Harada H; Oota E; Endo T; Takeda H
Xenobiotica; 2019 Jan; 49(1):106-119. PubMed ID: 29300135
[TBL] [Abstract][Full Text] [Related]
2. Effect of rovatirelin, a novel thyrotropin-releasing hormone analog, on the central noradrenergic system.
Ijiro T; Nakamura K; Ogata M; Inada H; Kiguchi S; Maruyama K; Nabekura J; Kobayashi M; Ishibashi H
Eur J Pharmacol; 2015 Aug; 761():413-22. PubMed ID: 26142830
[TBL] [Abstract][Full Text] [Related]
3. Human mass balance, pharmacokinetics and metabolism of rovatirelin and identification of its metabolic enzymes
Kobayshi K; Abe Y; Kawai A; Furihata T; Harada H; Endo T; Takeda H
Xenobiotica; 2019 Dec; 49(12):1434-1446. PubMed ID: 30747023
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic Drug Interactions of an Orally Available TRH Analog (Rovatirelin) With a CYP3A4/5 and P-Glycoprotein Inhibitor (Itraconazole).
Kobayashi K; Abe Y; Kawai A; Furihata T; Endo T; Takeda H
J Clin Pharmacol; 2020 Oct; 60(10):1314-1323. PubMed ID: 32459872
[TBL] [Abstract][Full Text] [Related]
5. Rovatirelin ameliorates motor dysfunction in the cytosine arabinoside-induced rat model of spinocerebellar degeneration via acetylcholine and dopamine neurotransmission.
Ijiro T; Yaguchi A; Yokoyama A; Kiguchi S
Clin Exp Pharmacol Physiol; 2022 Sep; 49(9):950-958. PubMed ID: 35637550
[TBL] [Abstract][Full Text] [Related]
6. Ameliorating effect of rovatirelin on the ataxia in rolling mouse Nagoya.
Ijiro T; Yaguchi A; Yokoyama A; Abe Y; Kiguchi S
Eur J Pharmacol; 2020 Sep; 882():173271. PubMed ID: 32534077
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and evaluation of in vivo anti-hypothermic effect of all stereoisomers of the thyrotropin-releasing hormone mimetic: Rovatirelin Hydrate.
Kobayashi N; Sato N; Sugita K; Takahashi K; Sugawara T; Tada Y; Yoshikawa T
J Pept Sci; 2019 Dec; 25(12):e3228. PubMed ID: 31713944
[TBL] [Abstract][Full Text] [Related]
8. Discovery of the Orally Effective Thyrotropin-Releasing Hormone Mimetic: 1-{
Kobayashi N; Sato N; Fujimura Y; Kihara T; Sugita K; Takahashi K; Koike K; Sugawara T; Tada Y; Nakai H; Yoshikawa T
ACS Omega; 2018 Oct; 3(10):13647-13666. PubMed ID: 30411045
[TBL] [Abstract][Full Text] [Related]
9. Effect of rovatirelin in patients with cerebellar ataxia: two randomised double-blind placebo-controlled phase 3 trials.
Nishizawa M; Onodera O; Hirakawa A; Shimizu Y; Yamada M;
J Neurol Neurosurg Psychiatry; 2020 Mar; 91(3):254-262. PubMed ID: 31937586
[TBL] [Abstract][Full Text] [Related]
10. Effects of taltirelin hydrate (TA-0910), a novel thyrotropin-releasing hormone analog, on in vivo dopamine release and turnover in rat brain.
Fukuchi I; Asahi T; Kawashima K; Kawashima Y; Yamamura M; Matsuoka Y; Kinoshita K
Arzneimittelforschung; 1998 Apr; 48(4):353-9. PubMed ID: 9608876
[TBL] [Abstract][Full Text] [Related]
11. Lack of behavioral tolerance by repeated treatment with taltirelin hydrate, a thyrotropin-releasing hormone analog, in rats.
Asai H; Asahi T; Yamamura M; Yamauchi-Kohno R; Saito A
Pharmacol Biochem Behav; 2005 Dec; 82(4):646-51. PubMed ID: 16368129
[TBL] [Abstract][Full Text] [Related]
12. Reversal of hemorrhagic shock in rats using the metabolically stable thyrotropin-releasing hormone analog taltirelin hydrate.
Asai H; Watanabe Y; Yamauchi-Kohno R; Doi O
J Recept Signal Transduct Res; 2011 Dec; 31(6):416-22. PubMed ID: 22044177
[TBL] [Abstract][Full Text] [Related]
13. Absorption of gamma-butyrolactone-gamma-carbonyl-L-histidyl-L-prolinamide citrate (DN-1417), an analog of thyrotropin-releasing hormone, in rats and dogs.
Yokohama S; Yoshioka T; Kitamori N
J Pharmacobiodyn; 1984 Aug; 7(8):527-35. PubMed ID: 6439851
[TBL] [Abstract][Full Text] [Related]
14. Intestinal absorption mechanisms of thyrotropin-releasing hormone.
Yokohama S; Yoshioka T; Yamashita K; Kitamori N
J Pharmacobiodyn; 1984 Jul; 7(7):445-51. PubMed ID: 6436461
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of the new thyrotropin releasing hormone analogue montirelin hydrate. 1st communication: plasma concentrations, metabolism and excretion after a single intravenous administration to rats, dogs and monkeys.
Sugimoto T; Hayashi T; Okita A; Morino A
Arzneimittelforschung; 1996 Feb; 46(2):106-13. PubMed ID: 8720298
[TBL] [Abstract][Full Text] [Related]
16. Metabolism and excretion of exogenous thyrotropin-releasing hormone in humans.
Bassiri RM; Utiger RD
J Clin Invest; 1973 Jul; 52(7):1616-9. PubMed ID: 4198107
[TBL] [Abstract][Full Text] [Related]
17. Correction to Discovery of the Orally Effective Thyrotropin-Releasing Hormone Mimetic: 1-{
Kobayashi N; Sato N; Fujimura Y; Kihara T; Sugita K; Takahashi K; Koike K; Sugawara T; Tada Y; Nakai H; Yoshikawa T
ACS Omega; 2019 Apr; 4(4):6977-6978. PubMed ID: 31459810
[TBL] [Abstract][Full Text] [Related]
18. Degradation of thyrotropin releasing hormone and a related compound by rat liver and kidney homogenate.
Visser TJ; Klootwijk W; Docter R; Hennemann G
Neuroendocrinology; 1976; 21(3):204-13. PubMed ID: 828243
[TBL] [Abstract][Full Text] [Related]
19. Disposition of vildagliptin, a novel dipeptidyl peptidase 4 inhibitor, in rats and dogs.
He H; Tran P; Yin H; Smith H; Flood D; Kramp R; Filipeck R; Fischer V; Howard D
Drug Metab Dispos; 2009 Mar; 37(3):545-54. PubMed ID: 19074976
[TBL] [Abstract][Full Text] [Related]
20. The pharmacokinetics of thyrotropin-releasing hormone (TRH) and deamido-TRH in the rat.
Safran M; Wu CF; Matys R; Alex S; Emerson CH
Endocrinology; 1984 Sep; 115(3):1031-7. PubMed ID: 6430680
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
